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Infants and children undergoing operations for complex con-genital heart disease form a group of extremely sick patientswho require specialized care in the postoperative period.1-4Treatment strategies to minimize morbidity and increase sur-
vival aim to improve cardiac function and optimize postoperative
hemodynamic parameters. Changes in thyroid hormone metabo-
lism have been documented in patients undergoing pediatric car-
diac surgery, as well as in adult patients.1-6 A recent study in chil-
dren undergoing cardiac surgery who received a single daily bolus
dose of triiodothyronine (T3) in the postoperative period showed
significant improvement in cardiac function and decreased post-
operative therapeutic intervention, especially in those patients
undergoing more complex surgical procedures.6 The present
report is the first prospective randomized study to use a continu-
ous infusion protocol to achieve normal steady-state serum T3 lev-
els in children for up to 7 days after cardiac surgery and to assess
clinical outcomes.
Methods
We evaluated 75 consecutive patients of either sex undergoing car-
diac surgery between the ages of birth and 18 years. The protocol
was approved by the institution’s committee on human rights in
research. Parents or guardians gave informed consent before the
operation, and patients older than 7 years of age gave assent.
Serum thyroid hormone levels were measured preoperatively,
immediately postoperatively, and then once a day. Criteria for
assignment to the treatment arm of the study included a serum
total T3 level of less than 40 ng/dL (or <60 ng/dL for newborns)
on postoperative days 0, 1, or 2 and a requirement for mechanical
ventilation. Patients randomized to the T3 treatment group
received continuous T3 infusion at 0.05 to 0.15 µg/kg of body
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weight per hour to maintain serum levels within the normal range
(80-200 ng/dL).4 Serum thyrotropin levels were analyzed to ensure
that the treatment dose did not render the patient chemically hyper-
thyroid.
The degree of inotropic support required was calculated as pre-
viously described by Wernovsky and colleagues.7 Cardiac rhythm
was continuously monitored with bedside monitors and telemetry.
The overall degree of postoperative care was analyzed by calculat-
ing the Therapeutic Interventional Scoring System (TISS) score.
Scores were given for 76 different therapeutic and monitoring pro-
cedures and reflected the invasiveness, intensity, and complexity of
care rendered to the patient.4,6
All demographic, baseline, and outcome variables were com-
pared by the Mann-Whitney test. Categoric variables were com-
pared by the Fisher exact test. Results are expressed as means ±
standard deviation. A 2-factor repeated-measures analysis of vari-
ance with group and day as the main effects and including the
interaction effect (group × day) in the model was initially carried
out for the serum T3 level. Bonferroni-adjusted pairwise compar-
isons between days were carried out.
Results
Twenty-eight of 75 patients were eligible for the study, with 14
patients randomized to T3 treatment. Figure 1 shows serum total T3
levels preoperatively and postoperatively in all study patients.
Serum T3 levels fell in all patients after operations with the lowest
values consistently measured after 24 and 48 hours. Patients receiv-
ing continuous T3 infusion achieved serum T3 values equivalent to
the mean preoperative levels within 24 hours of initiation of treat-
ment. Of the 28 study patients, serum T3 levels were equivalent at
the time of randomization. T3 treatment did not alter outcome mea-
sures in the randomized groups when all 28 patients were consid-
ered (Table 1). No differences were found for TISS score, inotrop-
ic score, or dose requirements for milrinone and furosemide.
Similarly, no significant differences were measured between the 2
groups for days of mechanical ventilation or length of hospital stay.
Nine patients within the overall study group were newborns
(<1 month of age); 5 were randomized to T3 treatment and 4 to the
untreated group (Table 1). No significant differences between the
T3-treated and untreated newborns were found with respect to the
number of patients requiring cardiopulmonary bypass, the total
bypass time, duration of crossclamping, and duration of hypother-
mic cardiac arrest. Twenty-four hours after initiation of T3 treat-
ment, the serum total T3 level was restored to normal at 130 ± 38
ng/dL, which was significantly higher than the level of 34 ± 7
ng/dL found in the untreated group.
The TISS score was not different on day 0 of randomization,
but on randomization days 1, 2, and 3, scores were significantly
lower (P = .037) in the T3-treated group (40 ± 7 ng/dL) compared
with the untreated group (49 ± 3 ng/dL), indicating lower postop-
erative management requirements (Table 1). T3 treatment signifi-
cantly decreased the need for inotropic support, as documented by
a lower mean daily inotropic score of 5 ± 3 compared with 23 ±
26 (P = .037) in the untreated group (Table 1). Mixed venous oxy-
gen saturation (MVO2) values were obtained in 8 newborns. The
mean MVO2 values at the time of randomization were similar at
53% ± 13% and 42% ± 10% for the T3-treated and untreated
patient groups, respectively. After 18 to 24 hours, the mean MVO2
increased to 70% ± 12% in the T3-treated group and remained
unchanged at 44% ± 18% in the untreated group. These differ-
ences, however, did not reach statistical significance because of
the small sample size. Although the length of hospital stay and
days of mechanical ventilation were not significantly different
between the 2 groups, the mean values showed a trend toward
shorter times in the T3-treated group (Table 1).
Discussion
Previous studies in adult5 and pediatric heart surgery patients1-4,6,8
have reported alterations in thyroid hormone metabolism, lead-
ing to significant decreases in postoperative serum total T3 levels
and normal or reduced serum thyrotropin and thyroxine levels. A
recent study showed that the half-life of serum T3 in children
after heart surgery was markedly decreased.9 Bettendorf and col-
leagues1,6 reported that a low serum T3 level in children after
cardiac surgery was a predictor of adverse outcome and that T3
treatment significantly improved cardiac function. Because we
and others have shown that thyroid hormones have both inotrop-
ic and vasoactive effects,10 we undertook a study to determine
Figure 1. Preoperative and postoperative serum total T3 levels in
pediatric patients undergoing operations for congenital heart
disease. Mean ± SE serum total T3 concentrations in all study
patients who were randomized to the T3-treated (n = 14) or the
untreated (n = 14) groups or were not eligible for randomization
(nonrandomized group, n = 47) are shown. Preoperative serum
samples were drawn in the operating room after induction of
anesthesia. Postoperative serum samples were drawn immedi-
ately after the operation. Day 0 of randomization into the study
represents serum total T3 values obtained 24 to 48 hours after
the operation. To convert values for T3 to nanomoles per liter,
multiply by 0.015. All data points between postoperative day 1
and 5 are significantly different among the 3 groups (P < .05).
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whether T3 replacement by continuous infusion of pediatric
patients after cardiac surgery would improve clinical outcome.
Evaluation of 75 patients showed that serum total T3 levels fell
predictably within 72 hours of the operation to a mean nadir
value of 42 ± 13 ng/dL. The present data are in agreement with
the results reported by Mainwaring,2 Bettendorf,1,6 and their col-
leagues, who showed that the fall in serum T3 was greater in
patients undergoing complex cardiac surgical procedures. In the
present study T3 treatment was accomplished safely with no
untoward changes in blood pressure, heart rate, or cardiac
rhythm. T3 treatment of the overall study group did not signifi-
cantly alter postoperative outcome measures, including the TISS,
days of mechanical ventilation, or overall length of hospital stay.
In contrast, newborn patients showed the tendency for a positive
therapeutic response to T3 treatment, as indicated by a signifi-
cantly lower TISS score and lower inotropic requirements that
persisted throughout the randomization period. As a measure of
cardiac output and peripheral perfusion, the MVO2 measure-
ments in the newborns showed a 17% increase after T3 treatment
compared with a 2% increase in the untreated group.
This positive postoperative outcome can be explained in part
by the known molecular effects of thyroid hormone to increase
cardiac contractility and to lower systemic vascular resistance in
cardiac disease,10 after cardiac surgery,4-6 and in the low-T3 syn-
drome.10 In conclusion, the present data suggest a therapeutic ben-
efit of T3 in the postoperative period by using a continuous infu-
sion protocol to normalize serum T3 levels in newborn patients
undergoing operations for complex congenital heart disease. A
prospective randomized study of greater statistical power will be
required to confirm these results.
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TABLE 1. Characteristics and treatment outcomes of the T3 study patients
Untreated T3 treatment P value
Overall study groups
No. of patients 14 14
Age (y) 3.2 ± 5.1 1.3 ± 2.4 1.000
TISS* 36 ± 12 39 ± 12 .765
Inotropic score* 11 ± 2 8 ± 4 .696
Mechanical ventilation (d) 4 ± 3 4 ± 2 .746
Postoperative hospital stay (d) 24 ± 29 23 ± 24 .747
Newborn patient subgroups
No. of patients 4 5
Age (d) 9.5 ± 11.6 4.6 ± 2.3 .805
TISS* 49 ± 3 40 ± 7 .037
Inotropic score* 23 ± 26 5 ± 3 .037
Mechanical ventilation (d) 6 ± 2 4 ± 2 .171
Postoperative hospital stay (d) 56 ± 38 18 ± 17 .109
Values are listed as means ± SD where shown. The normal range for serum total T3 is 80 to 200 ng/dL (1.2-3.0 nmol/L).
*Mean daily postrandomization score.
